PPD experts discuss current applications of translational research.
Overcome the challenges of early phase oncology studies with a global partner who can help to efficiently move your product to the next stage.
PPD offers clients a wide array of in-house capabilities across the full lifecycle of hematology and oncology drug development. Our services span early phase development through late stage research.
Early phase research is a critical arena for hematology and oncology drug development and PPD is the partner of choice to help clients execute Phase I and II studies.
PPD has conducted early phase hematology and oncology studies in all major early phase clinical research regions around the globe. Coupled with our extensive early phase experience, our technology capabilities and partnerships, dedicated facilities and global footprint help clients move their compounds to the next phase of development.
We understand the nuances and unique needs of post-approval hematology and oncology studies, including compassionate-use programs like expanded access programs. At PPD, our late stage expertise is therapeutically aligned and we offer a wide range of peri- and post-approval services from safety and risk-management to direct-to-patient services and epidemiology. PPD’s hematology and oncology peri- and post-approval knowledge helps us engage early, anticipate the demands of regulatory authorities, and provide economic modeling and product profiling to our clients.
PPD Hemotology/Oncology Innovation